Nogapendekin alfa inbakicept

Phase 3Protein / enzyme

IImmunityBio, Inc.

Nogapendekin alfa inbakicept is one of 72 small molecule programs targeting Lymphopenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphopeniaActive, not recruiting

SepsisNot yet recruiting

Myxoid LiposarcomaRecruiting

Non-Small Cell Lung Cancer Stage IVRecruiting

PneumoniaNot yet recruiting

LymphopeniaPreclinical

Active, not recruiting

SepsisPreclinical

Not yet recruiting

Myxoid LiposarcomaPhase 1

Recruiting

Non-Small Cell Lung Cancer Stage IVPreclinical

Recruiting

PneumoniaPhase 3

Not yet recruiting

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Nogapendekin alfa inbakicept

IImmunityBio, Inc.

Phase 3

2 2

Prevacid

Takeda

Preclinical

1 3

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 4

Innohep

Jazz Pharmaceuticals

Preclinical

1 5

Zantac 150

CChattem

Preclinical

2 6

Pepcid

KKenvue Brands

Preclinical

1 7

Aciphex

Akero Therapeutics

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Mucinex

RReckitt Benckiser LLC

Preclinical

1 10

Cancidas

FFresenius Kabi Taiwan Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Pneumonia

NCT07492888

Q4 2027

PreclinicalNot yet recruiting

Sepsis

NCT07783789

Q4 2029

Phase 3Not yet recruiting

Pneumonia

NCT07492875

Q3 2032

PreclinicalRecruiting

Non-Small Cell Lung Cancer Stage IV

NCT07355205

Phase 1Recruiting

Myxoid Liposarcoma

NCT07261657

Clinical

Trials by Indication[1]

Pneumonia2 trials

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Not yet recruiting·IImmunityBio, Inc.·Phase 3·NCT07492875·10 enrolled

Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT07492888·20 enrolled

Urothelial Cancer1 trial

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Withdrawn·VVadim S Koshkin·Phase 1·NCT07217496

Lymphopenia1 trial

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

Available·IImmunityBio, Inc.··NCT06956547

Pancreatic Cancer Resectable1 trial

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Withdrawn·IImmunityBio, Inc.·Phase 1·NCT07488884

Myxoid Liposarcoma1 trial

A Pilot Trial of N-803 in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Recruiting·NNorthwestern University·Phase 1·NCT07261657·8 enrolled

2 more indications

Sepsis1 trial

Phase 1b/2, Open-Label Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care in Critically Ill Adults With Sepsis

Not yet recruiting·IImmunityBio, Inc.·Preclinical·NCT07783789·49 enrolled

Non-small Cell Lung Cancer Stage IV1 trial

A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

Recruiting·WWashington University School of Medicine·Preclinical·NCT07355205·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Nogapendekin alfa inbakicept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nogapendekin alfa inbakicept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nogapendekin alfa inbakicept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: IImmunityBio, Inc.

Nogapendekin alfa inbakicept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2029

Q3 2032

Trials by Indication[1]

Pneumonia2 trials

Urothelial Cancer1 trial

Lymphopenia1 trial

Pancreatic Cancer Resectable1 trial

Myxoid Liposarcoma1 trial

Sepsis1 trial

Non-small Cell Lung Cancer Stage IV1 trial

References

Drug Info

Quick Facts

Related News